Hospital costs and length of stay associated with Rivaroxaban versus Low Molecular Weight Heparin/Warfarin in patients with Pulmonary Embolism with low-risk mortality

Trial Profile

Hospital costs and length of stay associated with Rivaroxaban versus Low Molecular Weight Heparin/Warfarin in patients with Pulmonary Embolism with low-risk mortality

Completed
Phase of Trial: Phase IV

Latest Information Update: 06 Dec 2016

At a glance

  • Drugs Rivaroxaban (Primary) ; Low molecular weight heparin; Warfarin
  • Indications Pulmonary embolism
  • Focus Therapeutic Use
  • Most Recent Events

    • 06 Dec 2016 Results (n=802) presented at the 58th Annual Meeting and Exposition of the American Society of Hematology
    • 06 Oct 2016 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top